APICHOPE PHARMACEUTICAL CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.24 CNY | -1.59% |
|
+4.46% | -25.44% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 6,339 | 10,200 | 9,894 | 13,394 | 9,986 | - | - |
| Enterprise Value (EV) 1 | 6,339 | 10,200 | 9,894 | 13,394 | 9,986 | 9,986 | 9,986 |
| P/E ratio | 28.1 x | 33.6 x | 36.2 x | 71 x | 20.7 x | 17.7 x | 29.7 x |
| Yield | - | - | 0.58% | 0.7% | 0.45% | 0.58% | - |
| Capitalization / Revenue | 3.78 x | - | 4.34 x | 5.35 x | 2.96 x | 2.33 x | 2.52 x |
| EV / Revenue | 3.78 x | - | 4.34 x | 5.35 x | 2.96 x | 2.33 x | 2.52 x |
| EV / EBITDA | - | - | 26.7 x | 34.4 x | 14.2 x | 11.6 x | 15.1 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | 5.12 x | 5.37 x | 3.55 x | 3.06 x | 3.36 x |
| Nbr of stocks (in thousands) | 425,993 | 426,174 | 429,162 | 449,027 | 449,027 | - | - |
| Reference price 2 | 14.88 | 23.93 | 23.05 | 29.83 | 22.24 | 22.24 | 22.24 |
| Announcement Date | 3/29/21 | 4/20/22 | 4/19/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,675 | - | 2,280 | 2,503 | 3,371 | 4,286 | 3,958 |
| EBITDA 1 | - | - | 369.9 | 389.8 | 703.9 | 862.3 | 662.4 |
| EBIT 1 | - | - | 282 | 213.9 | 478.8 | 630.7 | 417.4 |
| Operating Margin | - | - | 12.37% | 8.55% | 14.2% | 14.72% | 10.55% |
| Earnings before Tax (EBT) 1 | - | - | 326.4 | 244.2 | 556.8 | 659.8 | 447.6 |
| Net income 1 | - | 306.9 | 290.7 | 184.6 | 482.2 | 567.2 | 338.4 |
| Net margin | - | - | 12.75% | 7.37% | 14.3% | 13.23% | 8.55% |
| EPS 2 | 0.5296 | 0.7133 | 0.6373 | 0.4200 | 1.074 | 1.260 | 0.7500 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | 0.1333 | 0.2100 | 0.1000 | 0.1300 | - |
| Announcement Date | 3/29/21 | 4/20/22 | 4/19/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | 14.6% | 8.14% | 15.1% | 16.8% | 9.49% |
| ROA (Net income/ Total Assets) | - | - | - | - | 8.63% | 9.7% | - |
| Assets 1 | - | - | - | - | 5,585 | 5,848 | - |
| Book Value Per Share 2 | - | - | 4.500 | 5.550 | 6.270 | 7.260 | 6.610 |
| Cash Flow per Share 2 | - | - | 1.100 | 1.010 | 1.400 | 1.690 | 1.480 |
| Capex 1 | - | - | 606 | 334 | 276 | 291 | 529 |
| Capex / Sales | - | - | 26.56% | 13.36% | 8.18% | 6.78% | 13.36% |
| Announcement Date | 3/29/21 | 4/20/22 | 4/19/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
22.24
CNY
Average target price
32.98
CNY
Spread / Average Target
+48.28%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -25.44% | 1.38B | |
| +19.27% | 43.75B | |
| +27.47% | 22.06B | |
| +15.34% | 14.46B | |
| +12.33% | 13.62B | |
| +38.36% | 11.61B | |
| -9.54% | 6.9B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +9.64% | 5.32B |
- Stock Market
- Equities
- 300723 Stock
- Financials ApicHope Pharmaceutical Co., Ltd
